Across the 11,137 records in scope, the leading assignee holds 247 records, with the fifth-ranked assignee at 177 and the tenth at 114. That said, the top 10 combined represent only 15.6% of all records, so no single company dominates the field outright — ownership is fragmented across a broad set of pharmaceutical, biologics and equipment-focused filers. Anyone assessing competitive risk should look at the full ranked list rather than assume a two- or three-player market.

Filings rose steadily to a peak of 508 records in 2020, then fell to 244 by 2024, a -52% change over that three-year span. This should not be read as the technology losing relevance — publication typically lags actual filing by around 18 months, so the most recent one to two years in any dataset understate real activity. The honest read is a cooling from an unusually active 2020 rather than a confirmed multi-year decline.

US8800162B2, assigned to Syntegon Telstar Technologies, covers a method for monitoring and controlling a freeze drying process during the primary drying phase — specifically isolating the drying chamber, collecting pressure readings over a defined period, and correlating them with shelf temperature to characterise the sublimation front. It is a process-control patent rather than a device patent, meaning it constrains how a freeze dryer’s control software or firmware can algorithmically manage that phase, not the physical hardware itself. Anyone building automated cycle-control logic around pressure-and-temperature correlation during primary drying should review its claims closely.